COMP <GO>
MDLN vs MRK // EV/EBITDA & P/E VALUATION
Medline Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: MDLN 4
— MRK 11
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $32.12 (+0.38%) • MKT CAP: $42.07B
valuation
20.3x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MDLN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MDLN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 26.40% | 74.80% | -48.40 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.20% | 20.70% | -12.50 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.3x | 15.3x | +5.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.08% | 3.42% | -0.34 | MRK | /fcf-yield <GO> |
| Operating Margin | 7.80% | 34.30% | -26.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | 68.00% | 28.10% | +39.90 | MDLN | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 1.30% | +10.20 | MDLN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.50 | 5.19 | -2.69 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.60% | +0.70 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.6 | 56.9 | -25.30 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.92 | +0.19 | MDLN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 4.2x | 18.4x | -14.20 | MDLN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $42.07B | $361.02B | -$318.95B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MDLN REV | MRK REV | MDLN GROSS % | MRK GROSS % | MDLN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $28.43B | $65.01B | 26.4% | 74.8% | $1.30B | $12.36B |
| FY 2024 | $25.51B | $64.17B | 27.3% | 76.3% | $1.42B | $18.10B |
| FY 2023 | $23.23B | $60.12B | 44.0% | 44.0% | $639.6M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MDLN // BETA 1.11
MRK // BETA 0.92